Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01120639 · ClinicalTrials.gov registry record · Phase 1
Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01120639: Completed Phase 1 study, sponsored by Stanford University.
NCT01120639 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01120639, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved chemotherapy drug temozolomide
Interventions
- DRUG Temozolomide
- PROCEDURE Stereotactic Radiosurgery (SRS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-04 |
| Est. Completion | 2020-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01120639
The ClinicalTrials.gov registry entry for NCT01120639 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT01120639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01120639 about?
NCT01120639 is a clinical study titled "Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform". The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved chemotherapy drug temozolomide
What is the current status of trial NCT01120639?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-04. Estimated completion is 2020-11-15.
What interventions are being tested in trial NCT01120639?
The interventions under investigation include: Temozolomide (DRUG), Stereotactic Radiosurgery (SRS) (PROCEDURE).
Who is sponsoring clinical trial NCT01120639?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.